Top

Published in:

01-08-2018 | Focussed Research Review

Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge

Authors: Luana Calabrò, Aldo Morra, Robin Cornelissen, Joachim Aerts, Michele Maio

Published in: Cancer Immunology, Immunotherapy | Issue 8/2018

Abstract

Treatment of malignant pleural mesothelioma (MPM) represents a highly unmet medical need. Here, we discuss the results and therapeutic potential of first- and second-generation immunomodulatory antibodies targeting distinct immune checkpoints for the treatment of MPM, as well as their prospective therapeutic role in combination strategies. We also discuss the role of appropriate radiological criteria of response for MPM and the potential need of ad hoc criteria of disease evaluation in MPM patients undergoing treatment with immunotherapeutic agents.

Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89:716–724CrossRefPubMedPubMedCentral

Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S (2015) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(5 suppl):v31–9CrossRefPubMed

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed

Zalcman G, Mazieres J, Margery J, Greillier R, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivièr F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT) (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387(10026):1405–1414CrossRefPubMed

Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P (2015) Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16(4):447–456CrossRefPubMed

Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982CrossRefPubMedPubMedCentral

Kyi C, Postow MA (2016) Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy 8(7):821–837CrossRefPubMedPubMedCentral

Calabrò L, Danielli R, Sigalotti L, Maio M (2010) Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 37(5):460–467CrossRefPubMed

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33(10):1191–1196CrossRefPubMedPubMedCentral

10.

Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS (2011) Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 60(11):1509–1527CrossRefPubMedPubMedCentral

11.

Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG (2012) Immunotherapy 4(10):1011–1022CrossRefPubMed

12.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104–1111CrossRefPubMed

13.

Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M (2015) CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol Immunother 64(1):105–112CrossRefPubMed

14.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 3(4):301–309CrossRefPubMed

15.

Maio M, Scherpereel A, Calabrò L, Aerts J, Perez CS, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Atonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicenter, international, randomized, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18(9):1261–1273CrossRefPubMed

16.

Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407–416CrossRefPubMed

17.

Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66(5):551–564CrossRefPubMed

18.

Boussiotis VA (2016) Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375:1767–1778CrossRefPubMedPubMedCentral

19.

Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpfennig KW, Jänne PA, Sholl LM, Hammerman PS, Wong KK, Bueno R (2016) Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol Res 4:1038–1048CrossRefPubMed

20.

Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E (2015) Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 10(3):e0121071CrossRefPubMedPubMedCentral

21.

Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R (2016) Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol 11:1993–2005CrossRefPubMedPubMedCentral

22.

Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED (2014) B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9:1036–1040CrossRefPubMedPubMedCentral

23.

Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18(5):623–630CrossRefPubMed

24.

Quispel-Janssen J, Zago J, Schouten R et al (2017) A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies. J Thorac Oncol 12,(suppl abstr 13.0, presented at the World Conference on Lung Cancer 2016)

25.

Lievense LA, Sterman DH, Cornelissen R, Aerts JG (2017) Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med 196(3):274–282CrossRefPubMed

26.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM (2015) Combination therapy with anti-CTLA4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194(3):950–959CrossRefPubMed

27.

Larkin J, Hodi FS, Wolchok JD (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(13):1270–1271CrossRefPubMed

28.

Calabrò L, Morra A, Giannarelli D, Amato G, Bertocci E, D’Incecco A, Danielli R, Brilli L, Giannini F, Altomonte M, Di Giacomo AM, Maio M (2017) Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study. J Clin Oncol 35 (suppl; abstr 8558, presented at the American Society of Clinical Oncology (ASCO) 2017)

29.

Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Danielli R, Alessia Covre A, Lewis MC, Altomonte M, Di Giacomo AM, Maio M (2018) Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: the exploratory, non-randomised, phase 2, NIBIT-MESO-1 study. Lancet Resp Med. https://doi.org/10.1016/S2213-2600(18)30151-6 CrossRef

30.

Scherpereel A, Mazieres J, Greillier L, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Thiberville L, Urban T, Ligeza-poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G (2017) Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol 35(suppl; abstr LBA8507, presented at the American Society of Clinical Oncology (ASCO) 2017)

31.

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214CrossRefPubMed

32.

Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2):257–260CrossRefPubMed

33.

Frauenfelder T, Tutic M, Weder W, Gotti RP, Stahel RA, Seifert B, Opitz I (2011) Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma. Eur Respir J 38(1):162–168CrossRefPubMed

34.

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRefPubMed

35.

Hoos A, Wolchok JD, Humphrey RW, Hodi FS (2015) CCR 20th anniversary commentary: immune-related response criteria-capturing clinical activity in immuno-oncology. Clin Cancer Res 21(22):4989–4991CrossRefPubMed

36.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8 CrossRefPubMedPubMedCentral

37.

Noij DP, Boerhout EJ, Pieters-van den Bos IC, Comans EF, Oprea-Lager D, Reinhard R, Hoekstra OS, de Bree R, de Graaf P, Castelijns JA (2014) Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study. Eur J Radiol 83(7):1144–1151CrossRefPubMed

38.

Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, Enomoto S (2014) 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One 9(11):e109866CrossRefPubMedPubMedCentral

39.

Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G (2016) High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 6(10):1629–1640CrossRefPubMedPubMedCentral

40.

Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U (2016) Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy. J Nucl Med 57(10):1607–1611CrossRefPubMedPubMedCentral

41.

Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S (2017) Evaluation of response to immune checkpoint inhibitors: is there a role for positron emission tomography? World J Radiol 9(2):27–33CrossRefPubMedPubMedCentral

42.

Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98–106CrossRefPubMedPubMedCentral

Title: Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge
Authors: Luana Calabrò
Aldo Morra
Robin Cornelissen
Joachim Aerts
Michele Maio
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 8/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2191-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2018

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT

Immune-mediated cholangitis: is it always nivolumab’s fault?

Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study

Response to “Immune-mediated cholangitis: is it always nivolumab’s fault?”

Targeting myeloid-derived suppressor cells for cancer immunotherapy

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer